Article
The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.
Prevent Blindness opens nominations for 2 awards
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Envision Summit 2025: Importance of comanagement in glaucoma treatment
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma
TECLens, Inc. raises $9.3 million in Series A round for refractive technology